U.S. FDA Approved Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer
| | | | | |

U.S. FDA Approved Pfizer’s BRAFTOVI® Combination Regimen as First-Line Treatment of BRAF V600E-Mutant Metastatic Colorectal Cancer

On Dec. 20, 2024, Pfizer announced that the U.S. Food and Drug Administration (FDA) had approved BRAFTOVI® (encorafenib)…

FDA approved Alhemo® injection as once-daily prophylactic treatment to reduce frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B
| | | | |

FDA approved Alhemo® injection as once-daily prophylactic treatment to reduce frequency of bleeding episodes for adults and children 12 years of age and older with hemophilia A or B

On Dec. 20, 2024, Novo Nordisk announced that the U.S. Food and Drug Administration (FDA) had approved Alhemo®…

Trichuriasis in Human Patients from Côte d’Ivoire Caused by Novel Species resistant to Albendazole/Ivermectin Combination Treatment
| | | | | | |

Trichuriasis in Human Patients from Côte d’Ivoire Caused by Novel Species resistant to Albendazole/Ivermectin Combination Treatment

On Dec. 18, 2024, the U.S. Centers for Disease Control and Prevention (CDC) reported a study with patient…